全文获取类型
收费全文 | 76篇 |
免费 | 2篇 |
专业分类
78篇 |
出版年
2021年 | 1篇 |
2019年 | 2篇 |
2017年 | 2篇 |
2016年 | 1篇 |
2015年 | 5篇 |
2014年 | 2篇 |
2013年 | 2篇 |
2012年 | 8篇 |
2011年 | 6篇 |
2010年 | 3篇 |
2009年 | 2篇 |
2008年 | 5篇 |
2007年 | 9篇 |
2006年 | 1篇 |
2002年 | 1篇 |
2000年 | 1篇 |
1996年 | 1篇 |
1991年 | 2篇 |
1988年 | 1篇 |
1987年 | 3篇 |
1986年 | 1篇 |
1985年 | 1篇 |
1984年 | 1篇 |
1983年 | 3篇 |
1982年 | 1篇 |
1974年 | 2篇 |
1973年 | 1篇 |
1970年 | 3篇 |
1968年 | 2篇 |
1966年 | 2篇 |
1962年 | 1篇 |
1960年 | 1篇 |
1940年 | 1篇 |
排序方式: 共有78条查询结果,搜索用时 10 毫秒
51.
Employing papain as the enzyme and agarose bound Ricinus communis agglutinin as the affinity gel, a glycoprotein has been isolated and purified from the surface of Ascaridia galli. The glycoprotein shows an apparent molecular weight of 68 kilo daltons and contains fucose, galactose, rhamnose and glucosamine as sugar moieties. Only 2% of its entire molecule has been found to possess alpha-helical configuration. 相似文献
52.
53.
Kher S Lake K Sircar I Pannala M Bakir F Zapf J Xu K Zhang SH Liu J Morera L Sakurai N Jack R Cheng JF 《Bioorganic & medicinal chemistry letters》2007,17(16):4442-4446
Structure-activity relationship studies on a series of Boc-indole derivatives as LXR agonists are described. Compound 1 was identified as an LXR agonist through structure-based virtual screening followed by high-throughput gene profiling. Replacement of the indan linker portion in 1 with an open-chain linker resulted in compounds with similar or improved in vitro potency and cellular functional activity. The Boc group at the N-1 position of the indole moiety can be replaced with a benzoyl group. The SAR studies led to the identification of compound 8, a potent LXRbeta agonist with an EC50 of 12 nM in the cofactor recruitment assay. 相似文献
54.
Synthesis and structure-activity relationship of 4-(2-aryl-cyclopropylamino)-quinoline-3-carbonitriles as EGFR tyrosine kinase inhibitors 总被引:1,自引:0,他引:1
Pannala M Kher S Wilson N Gaudette J Sircar I Zhang SH Bakhirev A Yang G Yuen P Gorcsan F Sakurai N Barbosa M Cheng JF 《Bioorganic & medicinal chemistry letters》2007,17(21):5978-5982
Synthesis and structure-activity relationship of a series of 4-(2-aryl-cyclopropylamino)-quinoline-3-carbonitrile derivatives as EGFR inhibitors is described. Compounds 29 and 30 showed potent in vitro inhibitory activity in the enzymatic assay as well as in the functional cellular assay. They are moderately selective against other types of tyrosine kinases. 相似文献
55.
In CAPRI rounds 6-12, RosettaDock successfully predicted 2 of 5 unbound-unbound targets to medium accuracy. Improvement over the previous method was achieved with computational mutagenesis to select decoys that match the energetics of experimentally determined hot spots. In the case of Target 21, Orc1/Sir1, this resulted in a successful docking prediction where RosettaDock alone or with simple site constraints failed. Experimental information also helped limit the interacting region of TolB/Pal, producing a successful prediction of Target 26. In addition, we docked multiple loop conformations for Target 20, and we developed a novel flexible docking algorithm to simultaneously optimize backbone conformation and rigid-body orientation to generate a wide diversity of conformations for Target 24. Continued challenges included docking of homology targets that differ substantially from their template (sequence identity <50%) and accounting for large conformational changes upon binding. Despite a larger number of unbound-unbound and homology model binding targets, Rounds 6-12 reinforced that RosettaDock is a powerful algorithm for predicting bound complex structures, especially when combined with experimental data. 相似文献
56.
Sircar A Sanni KA Shi J Gray JJ 《Journal of immunology (Baltimore, Md. : 1950)》2011,186(11):6357-6367
Camelids have a special type of Ab, known as heavy chain Abs, which are devoid of classical Ab light chains. Relative to classical Abs, camelid heavy chain Abs (cAbs) have comparable immunogenicity, Ag recognition diversity and binding affinities, higher stability and solubility, and better manufacturability, making them promising candidates for alternate therapeutic scaffolds. Rational engineering of cAbs to improve therapeutic function requires knowledge of the differences of sequence and structural features between cAbs and classical Abs. In this study, amino acid sequences of 27 cAb variable regions (V(H)H) were aligned with the respective regions of 54 classical Abs to detect amino acid differences, enabling automatic identification of cAb V(H)H CDRs. CDR analysis revealed that the H1 often (and sometimes the H2) adopts diverse conformations not classifiable by established canonical rules. Also, although the cAb H3 is much longer than classical H3 loops, it often contains common structural motifs and sometimes a disulfide bond to the H1. Leveraging these observations, we created a Monte Carlo-based cAb V(H)H structural modeling tool, where the CDR H1 and H2 loops exhibited a median root-mean-square deviation to natives of 3.1 and 1.5 ?, respectively. The protocol generated 8-12, 14-16, and 16-24 residue H3 loops with a median root-mean-square deviation to natives of 5.7, 4.5, and 6.8 ?, respectively. The large deviation of the predicted loops underscores the challenge in modeling such long loops. cAb V(H)H homology models can provide structural insights into interaction mechanisms to enable development of novel Abs for therapeutic and biotechnological use. 相似文献
57.
58.
Xie YF Lake K Ligsay K Komandla M Sircar I Nagarajan G Li J Xu K Parise J Schneider L Huang D Liu J Dines K Sakurai N Barbosa M Jack R 《Bioorganic & medicinal chemistry letters》2007,17(12):3367-3372
Design and synthesis of a series of 3-amino-4-(2-(2-(4-benzylpiperazin-1-yl)-2-oxoethoxy)phenylamino)cyclobutenedione derivatives as novel CCR1 antagonists are described. Structure-activity relationship studies led to the identification of compound 22, which demonstrated potent binding activity, functional antagonism of CCR1 as well as good species cross-reactivity. In addition, compound 22 also showed desirable pharmacokinetic profiles and was selected for in vivo studies in the mouse collagen-induced arthritis model. 相似文献
59.
Arvind Sivasubramanian Aroop Sircar Sidhartha Chaudhury Jeffrey J. Gray 《Proteins》2009,74(2):497-514
High‐resolution homology models are useful in structure‐based protein engineering applications, especially when a crystallographic structure is unavailable. Here, we report the development and implementation of RosettaAntibody, a protocol for homology modeling of antibody variable regions. The protocol combines comparative modeling of canonical complementarity determining region (CDR) loop conformations and de novo loop modeling of CDR H3 conformation with simultaneous optimization of VL‐VH rigid‐body orientation and CDR backbone and side‐chain conformations. The protocol was tested on a benchmark of 54 antibody crystal structures. The median root mean square deviation (rmsd) of the antigen binding pocket comprised of all the CDR residues was 1.5 Å with 80% of the targets having an rmsd lower than 2.0 Å. The median backbone heavy atom global rmsd of the CDR H3 loop prediction was 1.6, 1.9, 2.4, 3.1, and 6.0 Å for very short (4–6 residues), short (7–9), medium (10–11), long (12–14) and very long (17–22) loops, respectively. When the set of ten top‐scoring antibody homology models are used in local ensemble docking to antigen, a moderate‐to‐high accuracy docking prediction was achieved in seven of fifteen targets. This success in computational docking with high‐resolution homology models is encouraging, but challenges still remain in modeling antibody structures for sequences with long H3 loops. This first large‐scale antibody–antigen docking study using homology models reveals the level of “functional accuracy” of these structural models toward protein engineering applications. Proteins 2009; 74:497–514. © 2008 Wiley‐Liss, Inc. 相似文献
60.